Lexaria Bioscience

LEXX

----

Current ValuationThe current P/E ratio is -0.75, above the reasonable range, cheaper than 3.6% of the time in the past 5 years, and the industry ranks 106/255, the industry Median -1.04.

-0.746xP/E

Stock price$3.49Earnings per share$-4.68

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

03876114152

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
BAYZFUSBayer Aktiengesellschaft	-27.19x	--	$54.78B
BAYRYUSBayer	-27.29x	--	$54.98B
VTRSUSViatris	-53.23x	107.68%	$21.86B
ELANUSElanco Animal Health	-57.90x	130.52%	$11.52B
AXSMUSAxsome Therap	-39.48x	20.27%	$7.57B
VREOFUSVIREO GROWTH INC	-104.02x	--	$6.98B
CURLFUSCuraleaf Holdings, Inc.	-121.67x	--	$6.33B
BLTEUSBelite Bio	-60.88x	29.87%	$6.23B
MANEUSVeraDermics	-55.96x	97.44%	$5.84B
DFTXUSDefinium Therapeutics	-13.80x	54.55%	$4.88B
EWTXUSEdgewise Therapeutics	-21.42x	187.50%	$4.22B
AMLXUSAmylyx Pharmaceuticals	-23.82x	1.76%	$3.62B
RGCUSRegencell Bioscience	-284.11x	--	$3.32B
TARSUSTarsus Pharmaceuticals	-70.67x	345.28%	$3.28B
ELVNUSEnliven Therapeutics	-30.61x	5.59%	$3.24B
BHCUSBausch Health	-3.65x	511.90%	$3.07B
MBXUSMBX Biosciences	-25.80x	31.12%	$2.69B
SUPNUSSupernus Pharma	-55.56x	52.94%	$2.44B
PHVSUSPharvaris BV	-11.88x	10.43%	$2.35B
PRGOUSPerrigo	-1.26x	78.81%	$2.19B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.